DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Australia
  • /
  • Healthcare
Author Program NEWCreate Narrative
IDX logo

Integral Diagnostics Limited Stock Price

ASX:IDX Community·AU$849.3m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 22 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

IDX Share Price Performance

AU$2.28
-0.61 (-21.11%)
​
AU$3.11
Fair Value
AU$2.28
-0.61 (-21.11%)
26.8% undervalued intrinsic discount
AU$3.11
Fair Value
Price AU$2.28
AnalystConsensusTarget AU$3.11
AnalystLowTarget AU$2.22
AnalystHighTarget AU$3.60
Mon, 11 May 26
Fair ValueAU$3.11
Share Pricen/a

IDX Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value AU$3.11 26.8% undervalued intrinsic discount

MRI Licensing And Lung Screening Will Expand Imaging Potential

0users have liked this narrative
0users have commented on this narrative
14users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value AU$2.22 2.7% overvalued intrinsic discount

MRI Deregulation And Teleradiology Expansion Will Shape Modest Future Earnings Improvements

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value AU$3.6 36.7% undervalued intrinsic discount

AI And Teleradiology Expansion Will Drive Long Term Diagnostic Imaging Leadership

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
IDX logo
Integral Diagnostics
36.7% undervalued intrinsic discount

AI And Teleradiology Expansion Will Drive Long Term Diagnostic Imaging Leadership

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 20 Aug
Read Narrative
IDX logo
Integral Diagnostics
26.8% undervalued intrinsic discount

MRI Licensing And Lung Screening Will Expand Imaging Potential

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 11 May
Read Narrative
IDX logo
Integral Diagnostics
2.7% overvalued intrinsic discount

MRI Deregulation And Teleradiology Expansion Will Shape Modest Future Earnings Improvements

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 26 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystHighTarget
IDX logo

IDX: Neutral Upgrade And 2026 Guidance Will Support Improved Risk Reward

Fair Value: AU$3.6 36.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
IDX logo

IDX: Trimmed Outlook And Neutral Rating Will Define Near-Term Share Performance

Fair Value: AU$2.22 2.7% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
IDX logo

IDX: New Leadership And New Clinics Will Support Future Upside

Fair Value: AU$3.11 26.8% undervalued intrinsic discount
14 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Reasonable growth potential and fair value.

3 Risks
4 Rewards
View Full Analysis

Integral Diagnostics Limited Key Details

AU$788.6m

Revenue

AU$545.3m

Cost of Revenue

AU$243.4m

Gross Profit

AU$221.4m

Other Expenses

AU$21.9m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
0.059
30.86%
2.78%
50.2%
View Full Analysis

About IDX

Founded
1967
Employees
3049
CEO
Jason Martinez
WebsiteView website
www.integraldiagnostics.com.au

Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, allied health professionals, and patients in Australia and New Zealand. It offers medical diagnostic imaging services, such as magnetic resonance imaging, computed tomography, mammography, ultrasound, and radiography, as well as nuclear medicine, including positron emission tomography. The company was founded in 1967 and is headquartered in East Melbourne, Australia.

Recent IDX News & Updates

Recent updates

No updates

Integral Diagnostics Limited Competitors

4DX logo

4DMedical

Symbol: ASX:4DX
Market cap: AU$2.0b
REG logo

Regis Healthcare

Symbol: ASX:REG
Market cap: AU$1.4b
NAN logo

Nanosonics

Symbol: ASX:NAN
Market cap: AU$825.0m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide